ArticleBMC cancer2025
Hetrombopag for thrombocytopenia induced by concurrent or sequential chemoradiotherapy in patients with solid tumors: a double-cohort trial.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChemoradiotherapy-induced thrombocytopenia (CRT-IT) is a common and clinically significant complication in cancer patients, yet there are no severity-based treatment guidelines, and existing therapies are limited by safety concerns and practicality. This study aimed to evaluate the efficacy and safety of hetrombopag, an oral thrombopoietin receptor agonist, for the treatment of CRT-IT, and to explore individualized strategies based on the severity of CRT-IT.
methodsThis prospective, dual-cohort study enrolled adult cancer patients with CRT-IT. Cohort 1 (baseline platelet count [PLT] 30–50 × 10⁹/L) received hetrombopag (initial dose 5 mg or 7.5 mg orally once daily, for up to 14 days with dose adjustments as needed) plus recombinant human interleukin-11 (rhIL-11, 25–50 µg/kg subcutaneously once daily for 7–14 days). Cohort 2 (baseline PLT 50–75 × 10⁹/L) received hetrombopag monotherapy, with the same dosing regimen. Treatment was discontinued once PLT reached ≥ 100 × 10⁹/L or increased by ≥ 50 × 10⁹/L from baseline. The primary endpoints were the proportion of patients achieving PLT recovery to ≥ 75 × 10⁹/L and the median time to recovery.
resultsBetween March 2022 and June 2024, 28 patients were enrolled. In Cohort 1 (n = 10), six patients (60.0%) achieved PLT recovery to ≥ 75 × 10⁹/L, with a median time of 4.5 days (95% confidence interval [CI]: 2.0–not reached [NR]). In Cohort 2 (n = 18), 14 patients (77.8%) reached this threshold within a median time of 4.5 days (95% CI: 3.0–7.0). One patient from each cohort required rescue therapy (10.0% in Cohort 1; 5.6% in Cohort 2). Grade ≥ 3 treatment-emergent adverse events occurred in one patient per cohort (10.0% in Cohort 1; 5.6% in Cohort 2), but were not attributed to hetrombopag.
conclusionsHetrombopag, either as monotherapy or in combination with rhIL-11, demonstrated preliminary evidence of effectively and rapidly improving PLT in patients with CRT-IT, with an acceptable safety profile. As an oral agent, monotherapy may offer a convenient option for moderate thrombocytopenia, while combination therapy may be considered for more severe cases. These findings are based on a small, exploratory study, and further validation in larger, controlled trials is warranted.
trial registrationThis trial was registered with chictr.org.cn under the identifier ChiCTR2500099546 on 25 March 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.